Discovery and Mechanism of Action of a Novel Desloratadine Derivative Inhibiting Mycobacterium tuberculosis 3-Dehydroquinate Synthase
Journal of Chemical Information and Modeling · 27.07.2026 · 66 (14) · 8423-8438
DOI: 10.1021/acs.jcim.6c00496 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Chemical Information and Modeling, online erschienen am 14.07.2026. Verfasst von Aweke Mulu Belachew und 14 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou510530, China. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Loratadine, Phosphorus-Oxygen Lyases, Enzyme Inhibitors. Die Arbeit nennt 52 Literaturangaben. Gefördert von: State Key Laboratory of Respiratory Disease, Basic and Applied Basic Research Foundation of Guangdong Province, Guangzhou Municipal Science and Technology Project.
Abstract (Originalsprache)
Mycobacterium tuberculosis, the etiological agent of tuberculosis (TB), remains a leading cause of mortality from infectious disease worldwide. The continued emergence of multidrug-resistant strains highlights the urgent need for new therapeutic agents with novel mechanisms of action. Here, we report the discovery and comprehensive characterization of DL25, a synthetic desloratadine-derived small molecule exhibiting potent antimycobacterial activity (minimum inhibitory concentration (MIC) 2–4 μg/mL against multiple mycobacterial species). Using a supra-inhibitory DL25 selection strategy, we isolated and characterized spontaneous resistant mutants. Whole-genome sequencing identified recurrent mutations in aroB, which encodes 3-dehydroquinate synthase (DHQS), an essential enzyme of the shikimate pathway. Consistent with target involvement, aroB overexpression reduced susceptibility to DL25, while DL25 decreased DHQS-associated biochemical activity in vitro with an apparent IC50 of approximately 5.0 μg/mL. In addition, DL25 exhibited concentration- and time-dependent bactericidal activity and showed partial synergy with several established antitubercular agents. Structural modeling, molecular docking, and 100 ns molecular dynamics simulations supported stable binding of DL25 within the DHQS active site and identified interactions with residues implicated in substrate recognition and catalysis. Collectively, the genetic, biochemical, and computational findings support DHQS as a biologically relevant target associated with DL25 activity and establish DL25 as a promising lead-like scaffold for the development of future shikimate pathway-directed antimycobacterial agents. More broadly, this study demonstrates the value of integrating genetic, biochemical, and computational approaches for mechanism-guided antituberculosis drug discovery.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou510530, China.
- University of Chinese Academy of Sciences, Beijing100049, China.
- State Key Laboratory of Respiratory Disease, Guangzhou Medical University, Guangzhou510230, China.
- Guangzhou National Laboratory, Guangzhou510320, China.
- State Key Laboratory of Respiratory Disease, Guangzhou Chest Hospital, Guangzhou510095, China.
- China-New Zealand Joint Laboratory on Biomedicine and Health, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou510530, China.
ORCID-Profile: Aweke Mulu Belachew, Andrey E Shchekotikhin, H M Adnan Hameed, Tianyu Zhang
Förderung
- State Key Laboratory of Respiratory Disease
- Basic and Applied Basic Research Foundation of Guangdong Province
- Guangzhou Municipal Science and Technology Project
- The World Academy of Sciences
- Alliance of International Science Organizations
- Chinese Academy of Sciences
- China-Maurice Wilkins Centre (MWC) Program, Guangdong-New Zealand Bilateral Joint Funding
- National Basic Research Program of China (973 Program)
Zitieren
APA
Belachew, A. M., Li, H., Tian, X., Liu, Z., Fang, C., Feng, L., Liu, S., Yusuf, B., Hu, J., Vatlin, A. A., Shchekotikhin, A. E., Wang, S., Hameed, H. M. A., Lin, S., & Zhang, T. (2026). Discovery and Mechanism of Action of a Novel Desloratadine Derivative Inhibiting Mycobacterium tuberculosis 3-Dehydroquinate Synthase. Journal of Chemical Information and Modeling, 66(14), 8423-8438. https://doi.org/10.1021/acs.jcim.6c00496
Vancouver
Belachew AM, Li H, Tian X, Liu Z, Fang C, Feng L, et al. Discovery and Mechanism of Action of a Novel Desloratadine Derivative Inhibiting Mycobacterium tuberculosis 3-Dehydroquinate Synthase. Journal of Chemical Information and Modeling. 2026;66(14):8423-8438. doi:10.1021/acs.jcim.6c00496
BibTeX
@article{Belachew2026,
author = {Belachew, Aweke Mulu and Li, Haizhou and Tian, Xirong and Liu, Zhiyong and Fang, Cuiting and Feng, Liqiang and Liu, Shouping and Yusuf, Buhari and Hu, Jinxing and Vatlin, Aleksey A and Shchekotikhin, Andrey E and Wang, Shuai and Hameed, H M Adnan and Lin, Shuimu and Zhang, Tianyu},
title = {Discovery and Mechanism of Action of a Novel Desloratadine Derivative Inhibiting Mycobacterium tuberculosis 3-Dehydroquinate Synthase},
journal = {Journal of Chemical Information and Modeling},
year = {2026},
volume = {66},
number = {14},
pages = {8423--8438},
doi = {10.1021/acs.jcim.6c00496}
}
EUVIMED